BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 28274690)

  • 1. The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma.
    Takamori S; Toyokawa G; Taguchi K; Edagawa M; Shimamatsu S; Toyozawa R; Nosaki K; Seto T; Hirai F; Yamaguchi M; Shoji F; Okamoto T; Takenoyama M; Ichinose Y
    Clin Lung Cancer; 2017 Jul; 18(4):e303-e313. PubMed ID: 28274690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
    Wu TH; Lee LJ; Yuan CT; Chen TW; Yang JC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):230-236. PubMed ID: 29709339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.
    Raphael J; Massard C; Gong IY; Farace F; Margery J; Billiot F; Hollebecque A; Besse B; Soria JC; Planchard D
    Cancer Biomark; 2015; 15(2):151-6. PubMed ID: 25519011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.
    Hasan B; Greillier L; Pallis A; Menis J; Gaafar R; Sylvester R; Fennell DA; Baas P; Surmont V; Van Meerbeeck JP; O'brien ME
    Eur J Cancer; 2014 Nov; 50(16):2771-82. PubMed ID: 25155251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.
    Negi Y; Kuribayashi K; Funaguchi N; Doi H; Mikami K; Minami T; Takuwa T; Yokoi T; Hasegawa S; Kijima T
    In Vivo; 2018; 32(5):1169-1174. PubMed ID: 30150440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
    Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
    Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
    Otoshi T; Kataoka Y; Kaku S; Iki R; Hirabayashi M
    In Vivo; 2018; 32(2):445-450. PubMed ID: 29475935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.
    Beckett P; Edwards J; Fennell D; Hubbard R; Woolhouse I; Peake MD
    Lung Cancer; 2015 Jun; 88(3):344-8. PubMed ID: 25863904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.
    Koyuncu A; Koksal D; Ozmen O; Demirag F; Bayiz H; Aydogdu K; Berkoglu M
    J Cancer Res Ther; 2015; 11(1):216-22. PubMed ID: 25879365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Significance of Controlling Nutritional Status (CONUT) Score as a Novel Prognostic Parameter in Small Cell Lung Cancer.
    Yılmaz A; Tekin SB; Bilici M; Yılmaz H
    Lung; 2020 Aug; 198(4):695-704. PubMed ID: 32424800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma.
    Espinoza-Mercado F; Borgella JD; Berz D; Alban RF; Sarkissian A; Imai HTA; Soukiasian HJ
    Ann Thorac Surg; 2019 Sep; 108(3):889-896. PubMed ID: 31004585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study.
    Takamori S; Toyokawa G; Shimokawa M; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Hirai F; Seto T; Tagawa T; Takenoyama M; Ichinose Y; Maehara Y
    Ann Surg Oncol; 2018 Jun; 25(6):1555-1563. PubMed ID: 29500763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
    Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
    Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database.
    Zhuo M; Zheng Q; Chi Y; Jia B; Zhao J; Wu M; An T; Wang Y; Li J; Zhao X; Yang X; Zhong J; Chen H; Dong Z; Wang J; Zhai X; Wang Z
    Thorac Cancer; 2019 May; 10(5):1193-1202. PubMed ID: 30951250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative controlling nutritional status (CONUT) score as a predictor of long-term outcome after curative resection followed by adjuvant chemotherapy in stage II-III gastric Cancer.
    Liu X; Zhang D; Lin E; Chen Y; Li W; Chen Y; Sun X; Zhou Z
    BMC Cancer; 2018 Jun; 18(1):699. PubMed ID: 29954375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
    Lococo F; Torricelli F; Lang-Lazdunski L; Veronesi G; Rena O; Paci M; Casadio C; Piana S; Novellis P; Di Stefano TS; Ciarrocchi A; Billè A
    J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1584-1593.e2. PubMed ID: 31590954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
    Proto C; Signorelli D; Mallone S; Prelaj A; Lo Russo G; Imbimbo M; Galli G; Ferrara R; Ganzinelli M; Leuzzi G; Greco FG; Calareso G; Botta L; Gatta G; Garassino M; Trama A
    Clin Lung Cancer; 2019 Nov; 20(6):e652-e660. PubMed ID: 31377142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment Controlling Nutritional Status Score and Lactate Dehydrogenase as Predictive Markers of Survival in Patients with Malignant Peritoneal Mesothelioma.
    Wang QQ; Zheng GQ; Yang DL; Liang YF; Yin WJ; Su SS
    Nutr Cancer; 2018; 70(8):1264-1274. PubMed ID: 30663400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
    Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
    BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.